NextPlat (NASDAQ:NXPL) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of NextPlat (NASDAQ:NXPL) to a hold rating in a research note released on Thursday,Zacks.com reports.

Several other brokerages have also recently weighed in on NXPL. Weiss Ratings raised shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Litchfield Hills Research assumed coverage on shares of NextPlat in a research report on Wednesday. They issued a “buy” rating and a $11.00 price objective on the stock. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, NextPlat has an average rating of “Hold” and a consensus target price of $11.00.

NextPlat Price Performance

Shares of NextPlat stock opened at $6.15 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.56 and a quick ratio of 2.12. NextPlat has a one year low of $3.38 and a one year high of $11.10. The business’s 50 day simple moving average is $6.39 and its two-hundred day simple moving average is $5.93. The stock has a market capitalization of $16.67 million, a P/E ratio of -1.42 and a beta of 1.90.

NextPlat (NASDAQ:NXPL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.42) earnings per share for the quarter. NextPlat had a negative net margin of 23.14% and a negative return on equity of 58.05%. The company had revenue of $9.86 million for the quarter. Analysts forecast that NextPlat will post -0.55 EPS for the current year.

Institutional Trading of NextPlat

An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC acquired a new position in NextPlat Corp. (NASDAQ:NXPL) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.19% of NextPlat as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.30% of the company’s stock.

More NextPlat News

Here are the key news stories impacting NextPlat this week:

• Positive Sentiment: Litchfield Hills Research initiated coverage on NextPlat with a Buy rating and a $11.00 price target, suggesting substantial upside potential. Street Insider article
• Positive Sentiment: The analyst sees NextPlat moving toward profitability, forecasting FY2027 EPS of $0.57 and positive quarterly EPS in 2027, which may improve longer-term sentiment. Benzinga article
• Neutral Sentiment: New earnings estimates for FY2026 (-$0.55 EPS) and Q2 2026 (-$0.21 EPS) still indicate losses in the near term, limiting immediate upside. Tickerreport article
• Neutral Sentiment: Short interest data showed a decline earlier in the month, but the most recent update reported 0 shares short, making the data unusual and hard to interpret for trading impact. American Banking News article
• Negative Sentiment: The latest analyst estimates still call for losses through most of 2026, including Q3 2026 EPS of $0.00 and Q4 2026 EPS of $0.07, so investors may remain cautious about near-term earnings power. Benzinga article

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.